JP2020530493A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530493A5
JP2020530493A5 JP2020530423A JP2020530423A JP2020530493A5 JP 2020530493 A5 JP2020530493 A5 JP 2020530493A5 JP 2020530423 A JP2020530423 A JP 2020530423A JP 2020530423 A JP2020530423 A JP 2020530423A JP 2020530493 A5 JP2020530493 A5 JP 2020530493A5
Authority
JP
Japan
Prior art keywords
bacterial strain
pharmaceutical composition
bacterial
feces
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020530423A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530493A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/045592 external-priority patent/WO2019032572A1/en
Publication of JP2020530493A publication Critical patent/JP2020530493A/ja
Publication of JP2020530493A5 publication Critical patent/JP2020530493A5/ja
Pending legal-status Critical Current

Links

JP2020530423A 2017-08-07 2018-08-07 腸内の抗生物質耐性菌を除菌するための組成物及び方法 Pending JP2020530493A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762542033P 2017-08-07 2017-08-07
US62/542,033 2017-08-07
PCT/US2018/045592 WO2019032572A1 (en) 2017-08-07 2018-08-07 COMPOSITIONS AND METHODS FOR DECOLONIZING ANTIBIOTIC-RESISTANT BACTERIA IN INTESTINES

Publications (2)

Publication Number Publication Date
JP2020530493A JP2020530493A (ja) 2020-10-22
JP2020530493A5 true JP2020530493A5 (cg-RX-API-DMAC7.html) 2021-09-24

Family

ID=65272652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020530423A Pending JP2020530493A (ja) 2017-08-07 2018-08-07 腸内の抗生物質耐性菌を除菌するための組成物及び方法

Country Status (8)

Country Link
US (2) US20200093870A1 (cg-RX-API-DMAC7.html)
EP (1) EP3665181A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020530493A (cg-RX-API-DMAC7.html)
KR (1) KR20200037851A (cg-RX-API-DMAC7.html)
CN (1) CN111328331A (cg-RX-API-DMAC7.html)
AU (1) AU2018313765A1 (cg-RX-API-DMAC7.html)
CA (1) CA3072029A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019032572A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性t細胞の増殖または集積を誘導する作用を有する組成物
CA2892588A1 (en) 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
KR20200038506A (ko) 2017-08-07 2020-04-13 핀치 테라퓨틱스, 인코포레이티드 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법
WO2019079629A1 (en) * 2017-10-18 2019-04-25 Ascus Biosciences, Inc. IMPROVING POULTRY PRODUCTION BY ADMINISTERING A SYNTHETIC BIO-ASSEMBLY OF MICROBES OR PURIFIED STEM THEREFOR
AU2019253714A1 (en) 2018-04-10 2020-11-26 Siolta Therapeutics, Inc. Microbial consortia
MX2021007599A (es) * 2018-12-19 2021-10-13 Healthy Cow Corp Composiciones probióticas listas para utilizar y usos de las mismas.
WO2021016081A1 (en) 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders
CN114728026A (zh) * 2019-08-28 2022-07-08 未知君有限责任公司 包含细菌物种的组合物及与其相关的方法
AU2020354581A1 (en) 2019-09-24 2022-03-03 Prolacta Bioscience, Inc. Compositions and methods for treatment of inflammatory and immune diseases
JP7624449B2 (ja) 2019-10-07 2025-01-30 シオルタ・セラピューティクス,インコーポレイテッド 治療用医薬組成物
CA3158132A1 (en) * 2019-10-18 2021-04-22 Finch Therapeutics Holdings Llc Compositions and methods for delivering a bacterial metabolite to a subject
GB201915144D0 (en) * 2019-10-18 2019-12-04 Multigerm Uk Entpr Ltd Method of promoting SCFA production by gut microbiota
EP3838281A1 (en) * 2019-12-20 2021-06-23 4D Pharma Research Limited Compositions comprising bacterial strains
WO2021231804A2 (en) * 2020-05-13 2021-11-18 President And Fellows Of Harvard College Methods and compositions for suppressing inflammation induced by gut microbes
GB202007452D0 (en) 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
CA3188645A1 (en) 2020-08-14 2022-02-17 Prolacta Bioscience, Inc. Human milk oligosaccharide compositions for use with bacteriotherapies
WO2022050082A1 (ja) * 2020-09-01 2022-03-10 国立大学法人東北大学 乳汁中のIgA抗体含有量の増加剤
JP7852863B2 (ja) * 2020-09-30 2026-04-28 国立研究開発法人国立がん研究センター ルミノコッカッセ腸内菌投与による免疫チェックポイント阻害薬の抗腫瘍効果の増強
AU2021388169A1 (en) * 2020-11-25 2023-07-13 Seres Therapeutics, Inc. Designed bacterial compositions for treating graft-versus-host-disease
US20230149483A1 (en) * 2021-11-12 2023-05-18 Iowa State University Research Foundation, Inc. Short-chain fatty acid use to mitigate antimicrobial resistance and virulence gene transfer in the gut
JPWO2023100989A1 (cg-RX-API-DMAC7.html) * 2021-12-02 2023-06-08
KR102780901B1 (ko) * 2022-11-09 2025-03-17 주식회사 굿바이옴텍 베타-락탐계 항생제 내성 유전자 blaCTX-M-229 및 퀴놀론계 항생제 내성 유전자 qnrS를 갖는 신규한 다제내성 대장균 균주 및 이의 용도
CN116747227B (zh) * 2023-08-12 2025-07-25 杭州市第一人民医院 泊马度胺在制备抗细菌感染药物中的应用
AU2024370585A1 (en) 2023-11-05 2026-06-18 Human Biome S.A. Functional compositions and methods of use thereof in eradication and/or decolonization of antibiotic-resistant bacteria and restoration of healthy microbiota
WO2025093780A1 (en) * 2023-11-05 2025-05-08 Human Biome Institute S.A. The concept of drugs made with the gut microbiota and its components and the method of their administration to obtain effective therapeutic effects

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727061B2 (en) * 1997-02-20 2004-04-27 Cabtec, Inc. Methods for identifying species or Shigella and E. coli using operon sequence analysis
EP1238071B1 (en) * 1999-11-29 2008-04-23 Avi Biopharma, Inc. Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s rrnas and their uses
BR112013022927A2 (pt) * 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
CA2892588A1 (en) * 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
US8921335B2 (en) * 2012-01-31 2014-12-30 The Regents Of The University Of California Oral delivery of nucleic acid-based gene interfering agents by Salmonella
JP2016519664A (ja) * 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド ネットワークを基にした微生物組成物及び方法
KR102099503B1 (ko) * 2013-06-05 2020-04-09 리바이오틱스, 인코퍼레이티드 미생물상 복원 요법(mrt) 조성물
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
GB201519088D0 (en) * 2015-10-28 2015-12-09 Metabogen Ab The use of bacteria formulations
KR20200038506A (ko) * 2017-08-07 2020-04-13 핀치 테라퓨틱스, 인코포레이티드 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법

Similar Documents

Publication Publication Date Title
AU2010339573B2 (en) Compositions and method for treatment and prophylaxis of inflammatory bowel disease
US20210106629A1 (en) Compositions and Methods for Treating Inflammatory Bowel Diseases (IBDs) and Other Disorders
Tsilika et al. A four-probiotic preparation for ventilator-associated pneumonia in multi-trauma patients: results of a randomized clinical trial
Trop Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease
Alexandre et al. Probiotics: a new way to fight bacterial pulmonary infections?
JP2009537547A (ja) 生物学的治療組成物およびその使用
WO2012142605A1 (en) Rapid recolonization deployment agent
JP2019525944A (ja) 潰瘍性大腸炎を治療するための方法
JP2019502724A (ja) 腸内細菌叢を調節するための治療
Qasemi et al. The power of probiotics to combat urinary tract infections: A comprehensive review
JP2023550652A5 (cg-RX-API-DMAC7.html)
Faubion et al. Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad
WO2014011233A1 (en) Compositions and method for treatment and prophylaxis of inflammatory bowel disease
He et al. Efficacy of curcumin supplementation for the treatment and prevention of pouchitis after ileal pouch-anal anastomosis: a randomized controlled trial
US11529375B2 (en) Compositions and methods for treating diverticulitis and related disorders
Fakayode Correlation Between Reactive Oxygen Species and Synbiotics for Effective
Boian Local preoperative therapeutic actions in hirschsprungs disease in newborns and infants.
EA050195B1 (ru) Лечение микробного дисбиоза
Guercini et al. 97: Long Lasting Therapy for Recurrent Urinary Tract Infections in Women
Gionchetti et al. Probiotics in IBD: A Critical Review.
Burch Understanding the rationale and use of probiotics in the treatment of IBD
Kroeker et al. Probiotics in Pouchitis and Ulcerative Colitis
ATALAY THE USE OF PROBIOTICS IN GASTROINTESTINAL DISEASES
Lima et al. eBook on Inflammatory Bowel Disease
Calafiore et al. Gastroenterology and Hepatology Research